Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06336798 · ClinicalTrials.gov registry record · Phase 2

Bioenergetic Effect of Pioglitazone in CLD-PH

A Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Emory University.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT06336798 is a Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases that is actively recruiting participants, run by Emory University. The registered enrollment target is 20 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06336798, a Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).

Conditions Studied

Pulmonary Hypertension Pulmonary Hypertension Due to Lung Diseases

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone 30mg
  • DIAGNOSTIC_TEST Labs

Study Locations (1)

Georgia

  • Emory Healthcare System - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-17
Est. Completion 2028-02
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06336798

The ClinicalTrials.gov registry entry for NCT06336798 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06336798 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06336798 about?

NCT06336798 is a clinical study titled "Bioenergetic Effect of Pioglitazone in CLD-PH". The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to ...

What is the current status of trial NCT06336798?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-17. Estimated completion is 2028-02.

What conditions does trial NCT06336798 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases.

What interventions are being tested in trial NCT06336798?

The interventions under investigation include: Placebo (DRUG), Pioglitazone 30mg (DRUG), Labs (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06336798?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06336798 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Hypertension

All registered trials for this condition

Pulmonary Hypertension Due to Lung Diseases

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.